



(51) International Patent Classification:

A61K 9/00 (2006.01) *A61K 9/08* (2006.01)
A61K 31/135 (2006.01) *A61P 25/36* (2006.01)

(21) International Application Number:

PCT/EP2012/058792

(22) International Filing Date:

11 May 2012 (11.05.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

11166076.7 13 May 2011 (13.05.2011) EP

(71) Applicant (for all designated States except US): **EURO-CELTIQUE S.A.** [LU/LU]; 2, Avenue Charles de Gaulle, L-1653 Luxembourg (LU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **STRANG, John** [GB/GB]; c/o National Addiction Centre, Addiction Sciences Building, 4 Windsor Walk, Denmark Hill, London SE5 8AF (GB). **OKSCHE, Alexander** [DE/DE]; c/o Mundipharma GmbH, Mundipharma Straße 2, 65549 Limburg (DE). **HARRIS, Stephen** [US/US]; c/o Purdue Pharma L. P., One Stamford Forum, 201 Tresser Boulevard, Stamford, Connecticut 06901-3431 (US). **SMITH, Kevin** [GB/GB]; c/o Mundipharma Research Limited, Cambridge Science Park, Milton Road, Cambridge CB4 0GW (GB). **MOTTIER, Lucie Helene Jeanne** [FR/GB]; c/o Mun-

dipharma Research Limited, Cambridge Science Park, Milton Road, Cambridge CB4 0GW (GB).

(74) Agent: **BÜHLER, Dirk**; Maiwald Patentanwalts GmbH, Elisenhof, Elisenstr. 3, 80335 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE

(57) Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ≥ 0.5 mg naloxone HCl dissolved in an application fluid of a volume of ≤ 250 μ l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

